ReviewMolecular medicine reports2026
Non‑coding RNAs in epithelial‑mesenchymal transition of renal cell carcinoma (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dimethyl itaconate attenuates dextran sulfate sodium-induced ulcerative colitis in BALB/c mice: investigations on the TXNIP/NLRP3 inflammasome signaling pathway.Inflammopharmacology · 2026Article
- Advances in Exosome Research in Renal Cell Carcinoma: Mechanisms, Biomarkers, and Therapeutic Applications.International journal of nanomedicine · 2026Review
- Multi-omics insights into tumor grade progression in clear cell renal cell carcinoma: from molecular mechanisms to precision therapeutics.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is a malignant tumor originating from the epithelial cells of the renal tubules. RCC has a high propensity for distant metastasis, complicating clinical management due to the paucity of effective post‑metastatic therapeutic strategies and the associated poor prognosis. Epithelial‑mesenchymal transition (EMT) is a biological process in which cells switch from epithelial to mesenchymal characteristics. RCC cells undergoing EMT exhibit a higher grade of malignancy with enhanced invasiveness and metastatic capabilities, thereby markedly promoting the tendency for distant metastasis. Non‑coding RNAs (ncRNAs) are a group of functional RNAs that are not translated into proteins. ncRNAs serve key roles in RCC progression and one of the key mechanisms involved is through regulating the EMT process. The present study reviews the research on ncRNAs regulating EMT in RCC and their future clinical applications, highlighting their notable potential as novel diagnostic biomarkers and therapeutic targets to combat metastatic RCC in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.